Navigation Links
Neuralstem Announces Proposed Public Offering
Date:9/13/2012

ROCKVILLE, Md., Sept. 13, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today its intention, subject to market and other conditions, to commence a public offering of its common stock. Neuralstem intends to use the net proceeds from the offering for general corporate purposes, including research and development expenditures, working capital, capital expenditures, clinical trial expenditures and other general corporate purposes.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

Aegis Capital Corp. is acting as the sole book-running manager for the offering.

The offering is being made pursuant to a shelf registration statement that Neuralstem filed with the Securities and Exchange Commission ("SEC") and is effective.  A prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus relating to these securities may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com. Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Neuralstem
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information            
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuralstem Updates ALS Stem Cell Trial Progress
2. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
3. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
6. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
7. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
8. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
9. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
10. Misonix Announces New Distribution Agreement For Panama
11. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for ... by age and sex in these markets. GD epidemiology report is written ... high quality, transparent and market-driven, providing expert analysis of disease trends in ... , Italy , Spain , ...
(Date:2/4/2016)... -- The Senior Care Pharmacy Coalition (SCPC) today commended ... Jason Chaffetz (R-UT) and Ranking Member Elijah ... "Developments in the Prescription Drug Market," to examine ... abusive pharmacy benefit manager (PBM) pricing practices. ... Elijah Cummings (D-MD) are diligent, serious lawmakers committed ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... , ... Health and wellness is a topic that should concern all Americans; ... experiencing an illness. Migraines are a severe form of a headache and often are ... wish the pain on their worst enemy, the feeling can last for many hours ...
(Date:2/5/2016)... NJ (PRWEB) , ... February 05, 2016 , ... ... Primary Care for Patients with Rare Diseases, a continuing medical education (CME) event ... is the first of its kind—and a first for ACCORD, whose mission is ...
(Date:2/5/2016)... ... February 05, 2016 , ... KICVentures ( ... Career Development event in New York City on Thursday, January 21, 2016. ... of Mediacom, (both alumnus of the varsity Columbia soccer program) spoke at the ...
(Date:2/5/2016)... ... , ... Susan Polk Health Insurance Company recently released a report ... in 2016. To view the report, see below, or visit Susan Polk's blog. ... Obispo seniors who rely on Medicare health insurance and whose monthly income includes social ...
(Date:2/4/2016)... ... February 04, 2016 , ... Dr. Carol Francis ... on February 19-21, 2016, in Southern California . The International Hypnosis Federation 2016 ... 30 professional speakers, including Clinical Psychologist and Hypnotherapist Dr. Carol Francis ...
Breaking Medicine News(10 mins):